Tango Therapeutics Inc. has synthesized substituted piperidine-dione molecular glue degraders comprising E3 ubiquitin ligase-binding moiety and acting as HBS1-like protein (HBS1L; HBS1) degradation inducers for use in the treatment of cancer.
Mindrank AI Co. Ltd. and Mindrank Therapeutics (Suzhou) New Drug Research have disclosed new Wee1-like protein kinase (Wee1) and/or tyrosine-protein kinase Yes (YES1) inhibitors potentially useful for the treatment of cancer, inflammation and autoimmune diseases.
Changchun Genescience Pharmaceuticals Co. Ltd. has reported new parathyroid hormone receptor 1 (PTHR1) agonists potentially useful for the treatment of arthritis, fracture, hyperphosphatemia and more.
Ascletis Pharma (China) Co. Ltd. has patented new 2-phenyl-1,2,4-triazine-3,5(2h,4h)-dione derivatives acting as thyroid hormone receptor β (THR-β) agonists potentially useful for the treatment of diabetes, obesity, hyperlipidemia, fibrosis, hepatic steatosis, thyroid cancer and hypercholesterolemia, among others.
Resother Pharma ApS has divulged new N-formyl peptide receptor 2 (FPR2; FPRL1; LXA4) agonists potentially useful for the treatment of chronic inflammation.
K2 Medicines (Nanjing) Co. Ltd. has identified new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to a cyclin-dependent kinase 4 (CDK4)- and/or CDK4/6 dual-targeting moiety. They are designed for use in the treatment of cancer, neurodegeneration, viral infection, cardiovascular and inflammatory disorders.
A Beone Medicines I GmbH and Beone Pharmaceutical (Suzhou) Co. Ltd. patent details new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to an interleukin-1 receptor-associated kinase 1 (IRAK-1)- and IRAK-4-targeting moiety. They are described as useful for the treatment of cancer, inflammatory disorders and autoimmune diseases.
RSS
